The store will not work correctly when cookies are disabled.
3-(2,5-difluoro-4-methoxyphenyl)-2-ethyl-5-methyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine
ID: ALA4446107
PubChem CID: 155518354
Max Phase: Preclinical
Molecular Formula: C17H14F5N3O
Molecular Weight: 371.31
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: CCc1nn2c(C(F)(F)F)cc(C)nc2c1-c1cc(F)c(OC)cc1F
Standard InChI: InChI=1S/C17H14F5N3O/c1-4-12-15(9-6-11(19)13(26-3)7-10(9)18)16-23-8(2)5-14(17(20,21)22)25(16)24-12/h5-7H,4H2,1-3H3
Standard InChI Key: OBRJWTUERCDKOF-UHFFFAOYSA-N
Molfile:
RDKit 2D
26 28 0 0 0 0 0 0 0 0999 V2000
41.2228 -18.9151 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
42.6333 -19.7323 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.6333 -18.9151 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.9280 -18.5024 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.9280 -20.1367 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
41.2206 -19.7362 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.6210 -20.2852 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.9579 -21.0252 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.7656 -20.9333 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
41.9280 -17.6852 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.3404 -20.1419 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.3392 -20.9591 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
44.0487 -19.7343 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
44.0458 -20.5495 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
40.5553 -21.7363 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.8203 -20.1220 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.5648 -19.3466 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.7649 -19.1832 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.2223 -19.7954 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.4851 -20.5736 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.2844 -20.7333 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.4213 -19.6332 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
37.1613 -18.8585 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.1079 -18.7360 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
37.9456 -21.1874 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
39.7381 -21.7432 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 6 1 0
1 4 2 0
5 2 1 0
2 3 2 0
3 4 1 0
5 6 1 0
6 7 2 0
7 8 1 0
8 9 2 0
9 5 1 0
4 10 1 0
2 11 1 0
11 12 1 0
11 13 1 0
11 14 1 0
8 15 1 0
7 16 1 0
16 17 2 0
17 18 1 0
18 19 2 0
19 20 1 0
20 21 2 0
21 16 1 0
19 22 1 0
22 23 1 0
17 24 1 0
20 25 1 0
15 26 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 371.31 | Molecular Weight (Monoisotopic): 371.1057 | AlogP: 4.57 | #Rotatable Bonds: 3 |
Polar Surface Area: 39.42 | Molecular Species: NEUTRAL | HBA: 4 | HBD: ┄ |
#RO5 Violations: ┄ | HBA (Lipinski): 4 | HBD (Lipinski): ┄ | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: ┄ | CX Basic pKa: 1.65 | CX LogP: 4.19 | CX LogD: 4.19 |
Aromatic Rings: 3 | Heavy Atoms: 26 | QED Weighted: 0.63 | Np Likeness Score: -1.60 |
References
1. Vázquez-Villa H, Trabanco AA.. (2019) Progress toward allosteric ligands of metabotropic glutamate 7 (mGlu7) receptor: 2008-present., 10 (2): [PMID:30881607] [10.1039/C8MD00524A] |